-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
share two news
First, the official WeChat news of Yangzijiang Pharmaceuticals, the company's Shugeng Sodium Glucose Injection was approved and grabbed the first imitation
.
Sugammadex sodium is a specific binding neuromuscular blocking antagonist
.
The original research was developed by Merck & Co.
of the United States.
It was listed in Europe for the first time in July 2008 under the trade name Bridion.
It was launched in Japan and the United States in 2010 and 2015
Sugammadex sodium is a water-soluble modified γ-cyclodextrin drug that specifically binds to muscle relaxants through physical encapsulation to reverse the neuromuscular blockade effect
.
It is clinically used to reverse the state of muscle relaxation in patients with general anesthesia, and promote the recovery of spontaneous breathing and limb mobility
.
Merck's annual report shows that the annual sales of products in the global market in 2021 will be US$1.
532 billion, a year-on-year increase of 27%.
It is already a heavy product
According to Yaohai data, the sales of the original research have grown rapidly since the launch, reaching nearly 300 million yuan last year
.
Such a heavyweight variety is of course a popular domestic imitation.
Many large companies such as Kelun, Yangzijiang, Chia Tai Tianqing, and Hengrui have applied for listing, but 5 companies have failed to apply for listing
| declare enterprise | Date | Acceptance number |
| Changsha Ruhong Pharmaceutical Technology Co. , Ltd. | 2022-03-07 | CYHS2200397 |
| 2022-03-07 | CYHS2200396 | |
| Hainan Ruizhi Pharmaceutical Technology Investment Co. , Ltd. | 2022-02-17 | CYHS2200321 |
| Beijing Tide Pharmaceutical Co. , Ltd. Another news is that Innovent Bio announced its 2021 financial report The financial report shows that Cinda's revenue in 2021 will be 4. 269 billion yuan, 4 billion yuan will come from drug sales, and 269 million yuan will come from licensing fees The annual report does not disclose the specific sales of the flagship product, sintilimab. According to the International Financial Reporting Standards, the loss during the year was 3. Sharing these two news, I want to say that it is really difficult to make medicine It's hard to make generics It is more difficult to make innovative drugs While maintaining high investment in research and development, Innovent is also investing heavily in market sales I carefully studied the product pipeline of the next company.
According to the progress of the declaration, it will take time for the follow-up new products to be launched.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
Welcome to ECHEMI 
|
